Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz
This article was originally published in The Pink Sheet Daily
Executive Summary
Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.